Remote Approaches for Optimizing Weight Loss (Elevate Weight Loss Trial)
The Miriam Hospital · with National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · NCT06875622
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18+ · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 490
- US sites recruiting
- 1
- Study start
- March 3, 2025
- Record last updated
- March 18, 2025
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The purpose of this trial is to compare two delivery formats for weight loss (automated online program vs. group-based videoconference program) and to examine the added effect of individual coaching (vs. no coaching) for individuals with overweight or obesity. All participants enrolled in this study will receive a 12-month behavioral weight loss program (varying in delivery format and individual support), and will be provided with weight loss, calorie intake, and exercise goals. Assessments will occur at baseline, 6 (mid-treatment), 12 (post-treatment), and 18 months (following 6 months of no intervention). We will also seek to determine which combination of intervention approaches works best for whom and develop algorithms which can be used to refer patients into remote programs in clinical settings or future trials.
Being studied: Automated online weight loss program; Individual coaching; Group-based, videoconference-delivered weight loss
Conditions: Obesity/therapy
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Body Mass Index between 25-45 kg/m2
- Daily, home Internet access
Exclusion Criteria
- Currently pregnant, planning to become pregnant within the next 18 months, or pregnant within the past 6 months
- Current or recent enrollment (\<2 years) in a weight loss program
- Presence of any medical condition for which exercise, weight loss, or dietary restriction is contraindicated
- Recent weight loss (≥10 pounds within the past 6 months)
- Currently taking weight loss medications or history of bariatric surgery
- Inability to walk 2 blocks without stopping
- Non-English speaking
- A member of one's household is participating in the study
- History of anorexia or bulimia nervosa
Recruiting US locations
The Miriam Hospital's Weight Control and Diabetes Research Center
Providence, RI 02903
Site contact: Jessic Unick, PhD · 401-793-8966 · junick@brownhealth.org
Study contacts (from the official record)
- Jessica L Unick, PhD · 401-793-8966 · junick@brownhealth.org
- Jennifer Webster · 401-793-8946 · jwebster@brownhealth.org
Similar studies in Rhode Island
All weight loss studies in Rhode Island →- RecruitingPhase 3
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
Eli Lilly and Company
- Location
- Providence, RI + 36 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
Eli Lilly and Company
- Location
- Providence, RI + 34 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
Amgen
- Location
- East Greenwich, RI + 30 other US sites
- Eligibility basics
- Ages 18–99
- RecruitingPhase 3
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
Amgen
- Location
- East Greenwich, RI + 69 other US sites
- Eligibility basics
- Ages 18–99